Coherus Transforms to Focus Solely on Cancer Therapeutics

REDWOOD CITY, Calif., May 30, 2025 - Coherus Oncology, Inc., previously known as Coherus BioSciences Inc., has officially changed its name to better reflect its commitment to pioneering immuno-oncology treatments. As a company at the forefront of cancer immunotherapy, Coherus Oncology aims to become a central figure in the evolving field of combination therapies, as highlighted by board member Jill O’Donnell-Tormey, Ph.D. Dr. O’Donnell-Tormey, who has a rich background in cancer research, emphasized the potential of these innovative approaches to enhance cancer treatment.

Alexander Rudensky, Ph.D., Co-Chair of the Coherus Scientific Advisory Board, noted that the next significant advancements in cancer immunotherapy are likely to emerge from novel mechanistic strategies. These strategies are designed to work in synergy, optimizing clinical outcomes. One such promising target is CCR8+ regulatory T cells (Tregs), which offer a method to selectively diminish tumor-induced immune suppression, while minimizing the risk of severe autoimmune responses.

Theresa LaVallee, Ph.D., Chief Scientific and Development Officer of Coherus Oncology, reiterated the company's dedication to the cancer community. She outlined the company's focus on extending patient survival and enhancing quality of life through groundbreaking therapies that target the immune system and address resistance mechanisms. The company's goal is to set new standards in cancer care through these novel combinations.

Coherus Oncology is actively advancing a portfolio of innovative combination therapies aimed at overcoming immune resistance typical of current treatments. Central to its immuno-oncology platform is LOQTORZI® (toripalimab-tpzi), an advanced PD-1 inhibitor. LOQTORZI stands as the sole FDA-approved therapy for recurrent or metastatic nasopharyngeal carcinoma (NPC) when used alongside chemotherapy. The company is exploring additional indications with the hope of establishing LOQTORZI as the backbone for future combination treatments that may prolong patient survival.

In addition to LOQTORZI, Coherus Oncology is developing CHS-114, a selective antibody that targets and depletes CCR8+ Tregs without off-target effects. CHS-114 is currently undergoing Phase 1b trials in patients with advanced solid tumors, focusing on conditions such as head and neck squamous cell carcinoma and gastric cancer. Furthermore, casdozokitug, an IL-27 antagonist, has shown promising monotherapy results in non-small cell lung cancer (NSCLC) and renal carcinoma, as well as combination potential in liver cancer. A Phase 2 trial is evaluating casdozokitug combined with toripalimab and bevacizumab versus the combination of toripalimab and bevacizumab in first-line metastatic liver cancer cases.

The team at Coherus Oncology is composed of leading industry experts with extensive experience in oncology drug development and commercialization. The Scientific Advisory Board features pioneers in Treg immunology and related fields, while the Board of Directors includes figures from major organizations like the Cancer Research Institute, Merck, and Bristol Myers Squibb. This diverse expertise equips Coherus Oncology to navigate the rapidly changing oncology landscape effectively.

Coherus Oncology operates as an integrated commercial-stage company with a focus on immuno-oncology. The company boasts an approved PD-1 inhibitor, LOQTORZI, and a promising pipeline poised to address various cancers, including those affecting the liver, lungs, and head and neck. The strategic expansion of LOQTORZI's use in nasopharyngeal carcinoma, along with the development of new indications through collaborative and proprietary approaches, underscores Coherus Oncology's dedication to advancing cancer care.

For further information about LOQTORZI, you can access the U.S. Prescribing Information and important safety details on the company's website.